American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.
The noncovalent BTK inhibitor LOXO-305 demonstrated promising efficacy in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). LOXO-305 was well-tolerated and active in patients following multiple prior lines of therapy, including patients with and without BTK C481 mutations. Read More ›

CPX-351 plus 7 days of venetoclax was tolerable and demonstrated encouraging activity in patients with relapsed/refractory acute myeloid leukemia. Read More ›

Treatment with CD19-CAR T-cells in patients with chronic lymphocytic leukemia (CLL) and disease transformation was found to be safe and demonstrates a high rate of complete remission. Read More ›

An escalated 21-day CC-486 (oral azacitidine) dosing regimen was well-tolerated and restored remission in approximately 25% of patients with acute myeloid leukemia (AML) who relapsed with 5% to 15% blasts on-study in the QUAZAR AML-001 trial. Read More ›

The combination of umbralisib and ublituximab, referred to as U2, was well-tolerated and significantly improved progression-free survival when compared with standard of care in patients with both treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL). Read More ›

Overall survival hazard ratios based on adjusted simulated treatment comparisons numerically, but not statistically, favored glasdegib plus low-dose cytarabine (LDAC) over venetoclax plus LDAC. Read More ›

The informCLL registry of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) can help to resolve knowledge gaps that may be identified in the evaluation and treatment of patients with CLL/SLL. Read More ›

As salvage therapy in younger patients with relapsed/refractory acute myeloid leukemia (AML), the efficacy of 10-day decitabine + venetoclax is comparable to intensive chemotherapy regimens and is an appropriate bridge to allogeneic stem-cell transplantation. Read More ›

Primary results from the CAPTIVATE study demonstrate that fixed-duration treatment with ibrutinib plus venetoclax offers treatment-free remission for patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

Across multiple acute myeloid leukemia (AML) subgroups, venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile, representing an attractive option as a bridge to allo-SCT for adverse-risk, newly diagnosed, and relapsed/refractory (R/R) AML patients. Read More ›

Page 8 of 43

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications